We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

New Method Using DNA Nanoballs to Revolutionize Pathogen Detection

By LabMedica International staff writers
Posted on 08 Sep 2023
Image: Electronic detection of DNA nanoballs enables simple pathogen detection (Photo courtesy of 123RF)
Image: Electronic detection of DNA nanoballs enables simple pathogen detection (Photo courtesy of 123RF)

Throughout the recent COVID-19 pandemic, protein-based diagnostics played a significant role in rapid testing. However, developing high-quality antibodies for these methods is time-consuming. In contrast, nucleic acid-based approaches offer advantages in terms of development ease, sensitivity, and flexibility. Scientists have now pioneered a novel technique using DNA Nanoballs for pathogen detection that could simplify nucleic acid testing and revolutionize pathogen identification. Their research could pave the way for a simple electronic-based test to quickly and affordably identify various nucleic acids in diverse scenarios.

The methodology developed by researchers at Karolinska Institute (Stockholm, Sweden) combined Molecular Biology (specifically DNA Nanoball generation) with electronics (electric impedance-based quantification) to create this groundbreaking detection tool. They are cautiously optimistic about its potential to identify a range of pathogenic agents in real-world settings. The team modified an isothermal DNA amplification reaction called LAMP to produce tiny DNA nanoballs measuring 1-2μM if the pathogen was present in the sample. These nanoballs are then guided through tiny channels and electrically identified as they pass between two electrodes. The method has demonstrated impressive sensitivity, capable of detecting as few as 10 target molecules, and provides rapid results in under an hour using a compact, stationary system.

This label-free detection method has the potential to accelerate the development of new diagnostic kits. By combining affordable mass-produced electronics with lyophilized reagents, it could become a cost-effective, widely accessible, and scalable point-of-care device. Currently, the research team is actively exploring applications in fields such as environmental monitoring, food safety, virus detection, and antimicrobial resistance testing. They are also considering licensing options and establishing a startup to leverage this technology, having recently applied for a patent.

“Fast and accurate detection of genetic material is key for diagnosis, especially so in response to the emergence of novel pathogens,” said principal investigator Vicent Pelechano.

Related Links:
Karolinska Institute 

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Immunofluorescence Analyzer
IFA System
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group

Channels

Clinical Chemistry

view channel
Image: Tracking blood test trends alongside unexplained weight loss may help identify patients at increased cancer risk and support earlier investigation (Image Credit: 123RF)

Blood Test Patterns Improve Cancer Risk Assessment in Primary Care

Unexplained weight loss is a common but nonspecific presentation in primary care that can precede several types of cancer, making referral decisions difficult. Routine blood tests may produce borderline... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Pathology

view channel
Image Credit: Adobe Stock

Machine Learning Cytology Tool Improves Cancer Cell Identification

Cytological screening remains central to early cancer detection, but its accuracy depends heavily on expert interpretation of stained cells. Under conventional microscopy, malignant and reactive cells... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more